Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.
about
Treatment of relapsed and refractory multiple myelomaCurrent and emerging treatment options for patients with relapsed myelomaUse of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in KoreaNew criteria for response assessment: role of minimal residual disease in multiple myelomaThe clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentBendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Lenalidomide in multiple myeloma: current experimental and clinical data.Lenalidomide in multiple myeloma-a practice guideline.Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.Multiple myeloma in the marrow: pathogenesis and treatments.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveLenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.Continuous treatment in multiple myeloma - ready for prime time?Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma.Lenalidomide in multiple myeloma: Current status and future potential.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.Association of response endpoints with survival outcomes in multiple myeloma.Choosing treatment options for patients with relapsed/refractory multiple myeloma.Controversies in multiple myeloma: to transplant or not?Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisationAn update on the use of lenalidomide for the treatment of multiple myeloma.Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma.Multiple Myeloma Minimal Residual Disease.Pomalidomide in the treatment of relapsed multiple myeloma.Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.Lenalidomide in multiple myeloma.Outcomes of primary refractory multiple myeloma and the impact of novel therapies.Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.
P2860
Q26749180-AED901E1-C7AD-421A-BDD2-02CD824194C1Q26830878-1F50F47B-46D4-4138-A0E8-1A837B5C3842Q26992002-F199D44E-B798-4B37-8D53-34288370519FQ27027512-41C9CDE9-25FC-4BD8-83D1-D3F75B05AB7BQ33398044-A151AC93-3F0F-445F-AE15-639B5AFD0899Q33399416-23A3F461-3042-40D2-8D01-21974CF7D674Q33403183-1528E64F-10BC-49D0-8CB8-5993D564694FQ33404749-B8B69AD9-7515-4560-8925-86DEA140B3C6Q33414647-42488BA8-15E4-43BA-860D-368F770AF7D9Q33428098-6686C3D2-DD80-4E16-A516-F2101269E19AQ33437691-8D071314-99C1-47B1-8519-9D2D14EBD1D8Q34074803-03AAD7E4-7212-4ADF-A4E7-903D167FB2E2Q34656086-EE9818C6-8BE2-44D3-98B8-F5A79AE7700BQ36065299-D6ADDAE5-7877-4B97-BBCD-1C3B37F08C43Q36115680-15E5C8E4-F72B-456F-86B5-FBF0A6966E76Q36725401-334E77AE-CA2B-4476-887F-7E0BAADCB4EBQ37835695-28596ED0-A8AF-404D-B6FB-FA6DD6B03BAEQ37851944-B62DCF80-A1E2-4A0C-9062-0C61E1FFE711Q37858327-C4AA6053-BFB6-4AE3-96D8-F964B88837D7Q37858523-84E1E24D-4AD3-41D9-8C8F-DC339B684833Q37862262-1B5F8759-D2AB-47E3-A9C4-477E73879079Q37936111-F6EE027E-3074-465C-B0EA-6521AAE2B47FQ37949201-2F31F846-64D2-416E-A4C3-D28C0853AD5BQ37976672-694CEC4B-C9CD-4C83-A550-79088464FD94Q38013995-861D4CFA-A631-46AB-BD6C-BB41EDAC5F53Q38031989-5BDE798D-9AB3-4697-B97E-E3D2EC882EECQ38122624-44DAE82E-1C52-4DB9-9B3F-D65E9E8310DDQ38170453-1C2FCAB5-D75C-4DD2-92CC-8E1651405735Q38242006-906952F3-72B8-41B7-8CEF-B6BC8BA98EABQ38446990-FCCDB650-2427-4896-A010-67D0124957F0Q38496485-A5BD8F06-DDA1-45F5-AEDE-84121566C772Q38545607-6EA67BCD-1419-4FB1-A521-959CEDFD8052Q38714708-DD261D08-6F52-4C20-A14B-CF0FAC4BAA50Q38970590-33C583BC-F247-405F-80FE-53411474EDFAQ39388200-632D3E16-1604-43F8-BE60-1F0A1DE91E41Q39524467-C5141D69-FA4E-4EF6-9A0A-0EBC7C82B041Q41114130-1E054C15-8E6F-4607-81EF-079EC0268D0EQ41543966-46285DDE-4C0D-4420-9033-8CA8458D4E50Q41602673-053E6840-60ED-4721-A17A-2AACF6F22823Q41655429-2709C8DD-003D-4553-BDC7-FA5440C3DD38
P2860
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Better quality of response to ...... r refractory multiple myeloma.
@ast
Better quality of response to ...... r refractory multiple myeloma.
@en
Better quality of response to ...... r refractory multiple myeloma.
@nl
type
label
Better quality of response to ...... r refractory multiple myeloma.
@ast
Better quality of response to ...... r refractory multiple myeloma.
@en
Better quality of response to ...... r refractory multiple myeloma.
@nl
prefLabel
Better quality of response to ...... r refractory multiple myeloma.
@ast
Better quality of response to ...... r refractory multiple myeloma.
@en
Better quality of response to ...... r refractory multiple myeloma.
@nl
P2093
P2860
P1433
P1476
Better quality of response to ...... r refractory multiple myeloma.
@en
P2093
Alessandro Corso
Andrew Spencer
Christine Chen
Donna M Weber
Jean-Luc Harousseau
Jerome B Zeldis
Marta Olesnyckyj
Michael Wang
Michel Attal
Robert D Knight
P2860
P304
P356
10.3324/HAEMATOL.2009.015917
P577
2010-05-11T00:00:00Z